Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

Financial Highlights:

- For the six months ended 30 June 2026, the Group's operating income amounted to approximately RMB311,619,000, representing an increase of 3.85% from that for the six months ended 30 June 2025;
- For the six months ended 30 June 2026, the Group's R&D expenses amounted to approximately RMB40,762,000, representing an increase of 50.32% from that for the six months ended 30 June 2025;
- As of the date of this announcement, the candidate drug molecule HX9428 of the core innovative drug project HXP056 independently developed by the Company is advancing simultaneously across clinical centres in China and the U.S.. In China, the Phase I clinical trial has been completed, and the Phase II dose expansion study and the second Phase II clinical study with a positive control are being conducted. In the U.S., the application for the Phase II clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the product has been granted Fast Track Designation (FTD) by the U.S. FDA. The Phase III pivotal registration clinical study of C019199 for the osteosarcoma indication has been approved by the Centre for Drug Evaluation (CDE), and the first patient has been successfully enrolled. The Investigational New Drug (IND) application for HXP089 for the treatment of glioblastoma (GBM), has also been approved by the Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), permitting the conduct of relevant clinical studies. The innovative drug pipeline has entered a phase of intensive harvests.

INTERIM RESULTS

The board (the "**Board**") of directors (the "**Director(s)**") of Fujian Haixi Pharmaceuticals Co., Ltd. (the "**Company**") is pleased to announce the unaudited consolidated interim results of the Company and its subsidiaries (collectively, the "**Group**") for the six months ended 30 June 2026 (the "**Period**" or the "**Reporting Period**") prepared in accordance with the China Accounting Standards for Business Enterprises ("**CASBE**"), together with the comparative figures for the corresponding period of 2025.

FINANCIAL INFORMATION

The financial information contained in this announcement relating to the Group's consolidated balance sheet as at 30 June 2026 and consolidated income statement for the six months ended 30 June 2026 and relevant notes is derived from the consolidated financial statements prepared in accordance with CASBE, which have been reviewed by the Audit Committee, the Board and the Company's external auditor, RSM China CPA LLP .

The Company has historically prepared its financial accounting reports in accordance with IFRS Accounting Standards. The Board considers that the adoption of CASBE for the preparation of the Company's financial accounting reports, with effect from the 2026 interim results and the 2026 interim report, is appropriate. Please also refer to the Company's announcement dated 11 August 2026 for the reasons for adopting CASBE.

CONSOLIDATED BALANCE SHEET

Item	Note 5	**As at 30 June 2026** ***RMB***	As at 31 December 2025 *RMB*
Current assets:			
Monetary funds	1	**1,018,978,308.55**	645,054,375.66
Financial assets held for trading	2	**172,386,138.83**	533,553,984.82
Derivative financial assets		**—**	—
Notes receivable		**26,288,423.87**	19,113,169.74
Accounts receivable	3	**29,210,546.44**	9,209,045.04
Accounts receivable financing		**—**	—
Advances to supplier	4	**13,643,972.62**	17,812,225.97
Other receivables		**1,082,716.63**	328,899.46
Including: Interest receivable		**—**	—
Dividends receivable		**—**	—
Inventories		**51,729,088.77**	56,099,983.16
Contract assets		**1,231,733.26**	1,302,763.66
Assets held for sale		**—**	—
Non-current assets due within one year		**—**	—
Other current assets	5	**237,727,973.01**	158,017,607.56
Total current assets		**1,552,278,901.98**	1,440,492,055.07
Non-current assets:			
Debt investments		**—**	—
Other debt investments		**—**	—
Long-term receivables		**477,313.50**	477,313.50
Long-term equity investments		**—**	—
Other equity instrument investments	6	**19,652,528.48**	20,281,268.58
Other non-current financial assets	7	**25,337,394.35**	23,383,745.50
Investment properties		**—**	—
Fixed assets		**253,164,162.97**	257,339,954.63
Construction in progress		**31,926,690.43**	36,268,994.98
Productive biological assets		**—**	—
Oil and gas assets		**—**	—
Right-of-use assets		**4,721,340.95**	5,534,765.95
Intangible assets		**27,472,584.81**	27,781,841.55
Development expenditures		**—**	—
Goodwill		**—**	—
Long-term deferred expenses		**1,471,271.70**	1,618,398.90
Deferred income tax assets		**6,655,457.07**	4,419,219.64
Other non-current assets		**43,130,086.71**	29,101,619.31
Total non-current assets		**414,008,830.97**	406,207,122.54
Total assets		**1,966,287,732.95**	1,846,699,177.61

Item	Note 5	**As at 30 June 2026** ***RMB***	As at 31 December 2025 *RMB*
Current liabilities:			
Short-term borrowings		**76,592,345.10**	78,513,500.00
Financial liabilities held for trading		**—**	—
Derivative financial liabilities		**—**	—
Notes payable		**—**	—
Accounts payable	8	**25,432,044.41**	31,699,365.37
Receipts in advance		**—**	—
Contract liabilities		**938,431.24**	1,693,496.59
Employee benefits payable		**3,549,456.18**	9,753,209.70
Taxes payable		**10,969,813.65**	15,064,798.89
Other payables		**103,285,174.46**	84,249,185.83
Including: Interest payable		**—**	—
Dividends payable		**—**	—
Liabilities classified as held for sale		**—**	—
Non-current liabilities due within one year		**5,818,315.43**	7,088,377.15
Other current liabilities		**113,897.09**	220,154.56
Total current liabilities		**226,699,477.56**	228,282,088.09
Non-current liabilities:			
Long-term borrowings		**—**	—
Bonds payable		**—**	—
Including: Preferred shares		**—**	—
Perpetual bonds		**—**	—
Lease liabilities		**4,208,357.61**	4,775,643.59
Long-term payables		**17,800,312.75**	19,768,294.97
Long-term employee benefits payable		**—**	—
Estimated liabilities		**—**	—
Deferred income		**48,340,271.99**	140,881.55
Deferred income tax liabilities		**—**	—
Other non-current liabilities		**—**	—
Total non-current liabilities		**70,348,942.35**	24,684,820.11
Total liabilities		**297,048,419.91**	252,966,908.20

Item	Note 5	**As at 30 June 2026** ***RMB***	As at 31 December 2025 *RMB*
Shareholders' equity:			
Share capital	9	**78,707,270.00**	78,707,270.00
Other equity instruments		**—**	—
Including: Preferred shares		**—**	—
Perpetual bonds		**—**	—
Capital reserve		**1,083,121,148.81**	1,083,121,148.81
Less: Treasury shares	10	**4,912,959.42**	—
Other comprehensive income		**(347,471.52)**	281,268.58
Special reserve			
Surplus reserve		**39,394,585.00**	39,394,585.00
Undistributed profit	11	**473,276,740.17**	392,227,997.02
Total equity attributable to owners of the parent company		**1,669,239,313.04**	1,593,732,269.41
Non-controlling interests		**—**	—
Total liabilities and owners' equity		**1,966,287,732.95**	1,846,699,177.61
Net current assets		**1,325,579,424.42**	1,212,209,966.98
Total assets less current liabilities		**1,739,588,255.39**	1,618,417,089.52

Note: The comparative balance sheet as at 31 December 2025 presented in the interim financial information is derived from the Group's annual consolidated financial statements for the year ended 31 December 2025. Such annual financial statements were originally prepared in accordance with IFRS Accounting Standards and were audited by an independent external auditor, who issued an unmodified audit opinion thereon on 30 March 2026 .

For the purpose of consistent presentation and compliance with the current reporting requirements under CASBE applicable to the current interim period, the comparative financial balances extracted from the IFRS-based annual financial statements have been subject to appropriate reclassification and presentation adjustments. No substantive recognition or measurement adjustments were involved in such reclassification; the adjustments solely aim to align the comparative financial information with the Group's current CASBE presentation basis, so as to enhance the period-on-period comparability of the interim financial information.

CONSOLIDATED INCOME STATEMENT

Item	Note 5	For the six months ended 30 June 2026 *RMB*	2025 *RMB*
I. Total operating income		**311,618,533.54**	300,075,435.14
Including: Operating income	12	**311,618,533.54**	300,075,435.14
II. Total operating costs		**224,661,989.85**	184,397,083.23
Including: Operating costs	12	**56,461,977.36**	40,614,937.46
Taxes and surcharges		**3,711,490.80**	2,497,169.17
Selling expenses		**99,356,317.01**	99,849,391.06
Administrative expenses		**12,611,364.81**	11,526,405.08
R&D expenses		**40,761,658.84**	27,116,284.90
Finance expenses		**11,759,181.03**	2,792,895.56
Including: Interest expenses		**3,621,162.90**	3,347,160.69
Interest income		**7,928,162.57**	569,945.24
Add: Other income		**6,366,228.05**	750,847.72
Investment income (losses are represented by "-")		**(10,527,184.67)**	1,268,974.55
Including: Income from investment in associates and joint ventures		**—**	—
Gains on derecognition of financial assets measured at amortised cost		**—**	—
Gains on net exposure hedging (losses are represented by "-")		**—**	—
Gains on changes in fair value (losses are represented by "-")		**2,864,803.46**	5,177,052.15
Credit impairment losses (losses are represented by "-")		**(932,821.35)**	(283,859.81)
Asset impairment losses (losses are represented by "-")		**(436,714.54)**	267,661.70
Gains on disposal of assets (losses are represented by "-")		**9,390.59**	—

Item	Note 5	For the six months ended 30 June 2026	2025
		RMB	*RMB*
III. Operating profit (losses are represented by "-")		**84,300,245.23**	122,859,028.22
Add: Non-operating income		**41.85**	38,839.22
Less: Non-operating expenses		**—**	7,897.40
IV. Total profit (total losses are represented by "-")		**84,300,287.08**	122,889,970.04
Less: Income tax expenses	13	**3,251,543.93**	15,084,115.57
V. Net profit (net losses are represented by "-")		**81,048,743.15**	107,805,854.47
(I) Categorized by continuity of operations			
1. Net profit from continuing operations (net losses are represented by "-")		**81,048,743.15**	107,805,854.47
2. Net profit from discontinued operations (net losses are represented by "-")		**—**	—
(II) Classified by ownership			
1. Net profit attributable to owners of the parent company(net losses are represented by "-")		**81,048,743.15**	107,805,854.47
2. Profit or loss attributable to non-controlling interests (net losses are represented by "-")		**—**	—
VI. Other comprehensive income, net of tax		**(628,740.10)**	—
(I) Other comprehensive income attributable to owners of the parent company, net of tax		**(628,740.10)**	—
(II) Other comprehensive income attributable to non-controlling interests, net of tax			
VII. Total comprehensive income		**80,420,003.05**	107,805,854.47
(I) Total comprehensive income attributable to owners of the parent company		**80,420,003.05**	107,805,854.47
(II) Total comprehensive income attributable to non-controlling interests			
VIII. Earnings per share			
(I) Basic earnings per share	15	**1.03**	1.60
(II) Diluted earnings per share		**1.03**	1.60

I. COMPANY PROFILE

福建海西新藥創制股份有限公司 (Fujian Haixi Pharmaceuticals Co., Ltd., being translation for identification purpose only) (hereinafter referred to as the "**Company**") was established in the People's Republic of China (the "**PRC**") as a limited liability company on 27 March 2012 and was converted into a joint stock company with limited liability on 15 November 2022 under laws of the PRC. The shares of the Company have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 20 October 2025 (the "Listing"). The address of the registered office and the principal place of business of the Company is Floor 3&4, Block B, No. 177 Jinda Road, Jianxin Town, Cangshan District, Fuzhou, Fujian Province, the PRC. Its ultimate controlling party is Dr. Kang Xinshan, who is also the Chairman and an executive Director of the Company.

The Company is a commercial-stage pharmaceutical company dedicated to developing, manufacturing and commercialising quality pharmaceutical products in China and globally, providing innovative and accessible treatment solutions for common therapeutic areas such as digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases.

The Group's interim consolidated financial statements for the six months ended 30 June 2026 comprise the interim consolidated balance sheet as at 30 June 2026, the interim consolidated income statement, the interim consolidated statement of changes in equity and the interim consolidated statement of cash flows for the six months ended 30 June 2026, together with selected explanatory notes (collectively referred to as the "**Interim Financial Information**"). Unless otherwise stated, the Interim Financial Information is presented in Renminbi ("**RMB**"), which is also the functional currency of the Company and its subsidiaries.

The Interim Financial Information was approved and authorised for issue by the Board of the Company on 28 August 2026.

The Interim Financial Information is unaudited but has been reviewed by the Company's external auditor.

II. BASIS OF PREPARATION FOR FINANCIAL STATEMENTS

1. Basis of preparation

The Company has historically prepared its financial statements in accordance with IFRS Accounting Standards for the purpose of information disclosure on the Stock Exchange. According to the Consultation Conclusions on Acceptance of Mainland Accounting and Auditing Standards and Mainland Audit Firms for Mainland Incorporated Companies Listed in Hong Kong issued by the Stock Exchange in December 2010, issuers incorporated in Chinese Mainland and listed in Hong Kong are allowed to prepare their financial statements using the CASBE, and accounting firms in Chinese Mainland recognized by the Ministry of Finance of the People's Republic of China (the "**PRC**") and the China Securities Regulatory Commission (the "**CSRC**") are permitted to provide services using the China Auditing Standards for Certified Public Accountants for those issuers. In order to unify the financial information disclosure between the Chinese Mainland and Hong Kong, subject to the approval by the Board, the Company will prepare its financial statements in accordance with the CASBE promulgated by the Ministry of Finance of the PRC and relevant regulations, commencing with the interim financial report for the period ended 30 June 2026.

The Group prepares financial statements on a going concern basis, based on actual transactions and events, in accordance with the relevant provisions of Accounting Standard for Business Enterprises No.32 - Interim Financial Reports issued by the Ministry of Finance, as well as the disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Hong Kong Companies Ordinance.

2. Going concern

The Company has assessed the ability of going concern for the 12 months since the end of the Reporting Period, finding no factors affecting the ability of going concern of the Company. Therefore, it is reasonable that the Company prepares the financial statements based on the going concern.

III. SIGNIFICANT ACCOUNTING POLICIES AND ACCOUNTING ESTIMATES

The following significant accounting policies and accounting estimates of the Company are formulated in accordance with the CASBE. Businesses not mentioned are subject to the relevant accounting policies in the CASBE.

1. Declaration of Compliance with the CASBE

The financial statements prepared by the Company meet the requirements of the CASBE and truly and completely reflect the Company's financial position, operating results, cash flows and other related information.

2. Accounting period

The Company's accounting year is from 1 January to 31 December in a calendar year. The accounting period for these financial statements is from 1 January 2026 to 30 June 2026.

3. Operating cycle

The Company's normal operating cycle is one year.

4. Functional currency

The Company adopts RMB as its functional currency.

IV. Taxation

1. Main tax types and tax rates

Tax type	Tax basis	Tax rate
Value-added tax	Taxable sale income	13%, 6%
Urban maintenance and construction tax	Turnover tax payable	5%
Educational surcharge	Turnover tax payable	3%
Local educational surcharge	Turnover tax payable	2%
Property tax	Balance after deducting 20.00% or 30.00% from the original value of the property	1.2%
Land use tax	Actually occupied land area	RMB2.4/m^2
Enterprise income tax	Taxable income	25%, 15%, 16.5%

Different enterprise income tax rates for the Company's subsidiaries

Name of taxpayer	Enterprise income tax rate
Haixi New Drug Creation (Fuzhou) Co., Ltd.*(海西新藥創制(福州)有限公司)	25%
Hong Kong Haixi Pharmaceuticals Limited	16.5%

2. Tax preference

(1) Enterprise income tax

On 4 December 2024, the Company obtained the High-tech Enterprise Certificate (Certificate No. GR202435002642) jointly issued by the Fujian Provincial Department of Science and Technology, Fujian Provincial Department of Finance, and Fujian Provincial Tax Bureau, State Taxation Administration. The certificate is valid for 3 years. According to Article 28 of the Enterprise Income Tax Law of the People's Republic of China, the applicable income tax rate for Fujian Haixi Pharmaceuticals Co., Ltd. during the Reporting Period was 15%.

(2) Value-added tax

Pursuant to the Announcement on the Value-Added Tax Additional Deduction Policy for Advanced Manufacturing Enterprises (Announcement of the Ministry of Finance and the State Taxation Administration [2023] No. 43), from 1 January 2023 to 31 December 2027, advanced manufacturing enterprises are permitted to apply an additional 5% deduction against their value-added tax (VAT) payable based on the deductible input VAT for the current period. The above preferential policy was applicable to the Company during the Reporting Period.

* for identification purpose only

V. NOTES TO ITEMS OF THE CONSOLIDATED FINANCIAL STATEMENTS

1. Monetary funds

Item	As at 30 June 2026	As at 31 December 2025
Cash on hand	**—**	—
Bank deposits	**973,889,390.33**	645,028,856.68
Other monetary funds	**45,088,918.22**	25,518.98
Total	**1,018,978,308.55**	645,054,375.66
Including: Total amount of overseas funds	**609,965,237.83**	434,484,976.73

2. Financial assets held for trading

Item	As at 30 June 2026	As at 31 December 2025
Financial assets measured at fair value through current profit or loss	**172,386,138.83**	533,553,984.82
Including: Structural deposit	**20,007,671.23**	20,258,356.17
Wealth management products	**152,378,467.60**	513,295,628.65
Total	**172,386,138.83**	533,553,984.82

3. Accounts receivable

Aging	As at 30 June 2026	As at 31 December 2025
Within 1 year	**30,731,891.42**	9,693,403.64
1-2 years	**16,944.00**	—
Sub-total	**30,748,835.42**	9,693,403.64
Less: Provision for bad debts	**1,538,288.98**	484,358.60
Total	**29,210,546.44**	9,209,045.04

Note: The above agings are presented based on the record date at the end of each reporting period.

4. Prepayments

Item	As at 30 June 2026	As at 31 December 2025
Within 1 year	**11,830,003.90**	14,174,008.31
1 to 2 years	**1,645,609.59**	3,638,217.66
2 to 3 years	**168,359.13**	—
Total	**13,643,972.62**	17,812,225.97

5. Other Current Assets

Item	As at 30 June 2026	As at 31 December 2025
Large-denomination certificates of deposit and time deposits	**232,701,113.77**	151,861,891.55
Deductible tax	**5,026,859.24**	6,155,716.01
Total	**237,727,973.01**	158,017,607.56

6. Other equity instrument investments

Item	As at 31 December 2025	Increase/decrease in the Period					As at 30 June 2026
		Additional investment	Reduced investment	Gains included in other comprehensive income in the Period	Losses included in other comprehensive income in the Period	Others	
Unlisted corporate equity	20,281,268.58	—	—	—	628,740.10	—	**19,652,528.48**
Total	20,281,268.58	—	—	—	628,740.10	—	**19,652,528.48**

Item	**Dividend income recognized in the Period**	**Cumulative gains included in other comprehensive income**	**Cumulative losses included in other comprehensive income**	**Reason for amount designated to be measured at fair value through other comprehensive income**
Unlisted corporate equity	—	(347,471.52)	—	Industry strategic investment
Total	—	(347,471.52)	—	

7. Other non-current financial assets

Item	**As at 30 June 2026**	As at 31 December 2025
Financial assets measured at fair value through profit or loss	**25,337,394.35**	23,383,745.50
Total	**25,337,394.35**	23,383,745.50

8. Accounts payable

Item	As at 30 June 2026	As at 31 December 2025
Payable for materials	**12,322,853.94**	13,306,768.49
Payable for engineering equipment	**12,119,236.22**	15,837,656.54
Other payables	**989,954.25**	2,554,940.34
Total	**25,432,044.41**	31,699,365.37

The analysis of the ageing of accounts payable based on the record date is as follows:

Item	As at 30 June 2026	As at 31 December 2025
Within 1 year	**17,136,451.32**	26,023,069.62
1 to 2 years	**8,267,196.28**	5,651,300.47
2 to 3 years	**28,396.81**	24,995.28
Total	**25,432,044.41**	31,699,365.37

9. Share capital

		Increase/decrease (+, -)					
Item	As at 31 December 2025	Issuance of new shares	Stock dividend	Conversion of reserves into share capital	Others	Sub-total	As at 30 June 2026
Total shares	78,707,270.00	—	—	—	—	—	**78,707,270.00**

10. Treasury shares

Item	As at 31 December 2025	Increase in the Period	Decrease in the Period	As at 30 June 2026
Treasury shares	—	4,912,959.42	—	**4,912,959.42**

11. Undistributed profit

Item	For the six months ended 30 June 2026	2025
Undistributed profit as at the end of the previous period before adjustment	**392,227,997.02**	226,932,617.90
Adjustment to total undistributed profit as at the beginning of the period ("+" for increase and "-" for decrease)	**—**	—
Undistributed profit as at the beginning of the period after adjustment	**392,227,997.02**	226,932,617.90
Add: Net profit attributable to owners of the parent company in the Period	**81,048,743.15**	177,028,649.12
Transfer-in of surplus reserves offsetting losses	**—**	—
Transfer-in of capital reserves offsetting losses	**—**	—
Less: Withdrawal of statutory surplus reserves	**—**	11,733,270.00
Withdrawal of discretionary surplus reserves	**—**	—
Withdrawal of general risk reserves	**—**	—
Ordinary share dividend payable	**—**	—
Ordinary share dividends converted to share capital	**—**	—
Undistributed profit as at the end of the period	**473,276,740.17**	392,227,997.02

12. Operating income and operating costs

	For the six months ended 30 June			
	2026		2025	
Item	**Revenue**	**Costs**	Revenue	Costs
Main business	**311,067,445.71**	**55,689,338.46**	299,666,640.06	40,415,534.55
Other business	**551,087.83**	**772,638.90**	408,795.08	199,402.91
Total	**311,618,533.54**	**56,461,977.36**	300,075,435.14	40,614,937.46

(1) Breakdown of main business revenue and main business cost

Item	For the six months ended 30 June			
	2026		2025	
	Revenue	**Costs**	Revenue	Costs
By product type				
Sale of pharmaceutical products	**311,067,445.71**	**55,689,338.46**	299,666,640.06	40,415,534.55
Total	**311,067,445.71**	**55,689,338.46**	299,666,640.06	40,415,534.55
By revenue recognition time				
Recognition of revenue at a point in time	**311,067,445.71**	**55,689,338.46**	299,666,640.06	40,415,534.55
Total	**311,067,445.71**	**55,689,338.46**	299,666,640.06	40,415,534.55

13. Income tax expenses

Item	For the six months ended 30 June	
	2026	2025
Current income tax expenses	**5,487,781.36**	13,267,851.96
Deferred income tax expenses	**(2,236,237.43)**	1,816,263.61
Total	**3,251,543.93**	15,084,115.57

14. Segment information

(1) Determination basis and accounting policies for reportable segments

Based on the Group's internal organisational structure, management requirements and internal reporting system, the Group's business operations are divided into 2 reportable segments. These segments are determined based on the financial information required for daily internal management of the Group. The Group's management regularly evaluates the operating results of these reportable segments to determine resource allocation and assess their performance.

The Group's reportable segments include:

① Innovative Drugs segment which focuses on the research and development of innovative drugs;

② Generic Drugs segment which focuses on the research and development, production and sales of generic drugs;

Information on segment reporting are disclosed according to the accounting policies and measurement standards adopted by each segment to report to the management, which are consistent with the accounting policies and measurement basis adopted to prepare the financial statements.

(2) Segment profit or loss

For the six months ended 30 June 2026/ As at 30 June 2026	**Innovative Drugs segment**	**Generic Drugs segment**	**Undistributed**	**Total**
Operating income	**—**	**311,618,533.54**	**—**	**311,618,533.54**
Segment profit/(loss)	**(32,907,138.65)**	**148,248,798.85**	**(31,041,373.12)**	**84,300,287.08**
Financing costs	**—**	**—**	**3,621,162.90**	**3,621,162.90**
Undistributed corporate income and expenses	**—**	**—**	**27,420,210.22**	**27,420,210.22**
Listing expenses	**—**	**—**	**—**	**—**
Supplementary information:	**—**	**—**	**—**	**—**
1. R&D expenses	**32,907,138.65**	**7,854,520.19**	**—**	**40,761,658.84**
2. Marketing expenses	**—**	**95,163,422.67**	**—**	**95,163,422.67**
3. Depreciation and amortization expenses	**—**	**9,700,720.57**	**965,489.38**	**10,666,209.95**
4. Changes in book value of other borrowings measured at amortized cost	**—**	**4,451,285.21**	**—**	**4,451,285.21**

(Continued)

For the six months ended 30 June 2025/ As at 30 June 2025	Innovative Drugs segment	Generic Drugs segment	Undistributed	Total
Operating income	—	300,075,435.14	—	300,075,435.14
Segment profit/(loss)	(19,640,910.07)	155,154,059.08	(12,623,178.97)	122,889,970.04
Financing costs	—	—	3,347,160.69	3,347,160.69
Undistributed corporate income and expenses	—	—	7,038,810.05	7,038,810.05
Listing expenses	—	—	2,237,208.23	2,237,208.23
Supplementary information:	—	—	—	—
1. R&D expenses	19,640,910.07	7,475,374.83	—	27,116,284.90
2. Marketing expenses	—	95,255,971.73	—	95,255,971.73
3. Depreciation and amortization expenses	—	1,876,661.52	592,255.78	2,468,917.30
4. Changes in book value of other borrowings measured at amortized cost	—	5,247,834.76	—	5,247,834.76

(3) Other segment information

① Revenue from sales of goods and rendering of services to third parties: None.

② Geographical information

All of the Group's non-current assets are located in Chinese Mainland, and all of the Group's external customers are also based in Chinese Mainland. Therefore, this announcement does not analyze the geographical segment business of its external customers.

③ Degree of dependency on main customers

Revenue from customers accounting for more than 10% of the Group's total revenue is as follows:

		For the six months ended 30 June	
Customer	**Revenue type**	**2026**	2025
Customer A	Sale of pharmaceutical products	**131,892,505.16**	129,596,902.26
Total		**131,892,505.16**	129,596,902.26

15. Earnings per share

	For the six months ended 30 June	
Item	**2026**	2025
Net profit attributable to ordinary shareholders of the Company	**81,048,743.15**	107,805,854.47
Weighted average number of outstanding ordinary shares	**78,706,778.49**	67,207,270.00
Earnings per share	**1.03**	1.60

16. Dividends

For the six months ended 30 June 2026, the Company did not pay any dividends.

2026 INTERIM REVIEW

The Company is a commercial-stage pharmaceutical company that integrates research and development ("R&D"), production and sales capacities, with a pipeline of innovative drug candidates. It has established a diversified product portfolio and pipeline in the largest and fastest growing therapeutic areas in China. As of the date of this announcement, the commercialised product portfolio primarily consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, musculoskeletal system diseases and pain disorders, nervous system diseases and inflammatory diseases. The innovative drug pipeline focuses on innovative drugs addressing significant unmet medical need in clinical practice, including two innovative oncology drug candidate under clinical trial, one potential first oral drug therapy for wet age-related macular degeneration (nAMD, a retinal disease caused by abnormal growth of blood vessels under the retina)/diabetic macular edema (DME, fluid leakage into macula from diabetes)/retinal vein occlusion (RVO, vision loss from blockage of retinal veins), and another innovative preclinical-stage drug candidates in respiratory diseases. All of the said innovative drug candidates are proprietarily discovered and developed in house.

The Company has obtained approval from the National Medical Products Administration (the "**NMPA**") for 17 generic drugs and established a pipeline of four innovative drug candidates as of 30 June 2026, making it a key market participant in the pharmaceutical industry in China. During the Reporting Period, the Company generated revenue from 15 approved products. To protect the said products and drug candidates throughout their lifecycle, the Company has established a global patent portfolio that consisted of 39 patents as of 30 June 2026, including 20 in overseas jurisdictions covering the U.S., Canada, Australia, Japan, Korea, Singapore, India and 29 European countries. In addition, the Company plans to actively explore opportunities to collaborate with multinational corporations (MNCs) to expand its international clinical research and commercialisation capacities.

During the Reporting Period, the Company has persisted in its development strategy of "fast-follow fuels innovation, and innovation shapes the future (仿製助力創新,創新驅動未來)" and has made further progress in all aspects of R&D, sales and marketing.

Market Positioning and Key Products

Key products related to digestive system diseases

The Company's commercialised product portfolio consisted of two drugs for digestive system diseases: (i) Anbili (安必力®), the first-to-market generic of mosapride citrate tablets that was regarded as passing the consistency evaluation in China and a generic of mosapride citrate tablets selected in the Fourth National volume-based procurement (VBP) Scheme and participated in the renewal of the 1st-8th batches of national VBP schemes; and (ii) Anliding (安立定®), a generic of rebamipide tablets selected in the provincial VBP scheme.

Key products related to cardiovascular system diseases

The Company's commercialised product portfolio consisted of seven drugs for cardiovascular system diseases: (i) Haihuitong (海慧通®), a generic of amlodipine besilate and atorvastatin calcium tablets, selected in the Eighth National VBP Scheme and participated in the renewal of the 1st-8th batches of national VBP schemes; (ii) Haibiping (海必平®), a generic of valsartan and amlodipine tablets (I) was selected in provincial VBP scheme and participated in the renewal of the 1st-8th batches of national VBP schemes; (iii) Haikexi (海可喜®), a generic of valsartan tablets selected in provincial VBP scheme and participated in the renewal of the 1st-8th batches of national VBP schemes; (iv) Haihuining (海惠寧®), a generic of bisoprolol fumarate and amlodipine besilate tablets; (v) Hailiping (海立平®), a generic of benidipine hydrochloride tablets; (vi) Shuanya (舒安亞®), a generic of nicergoline tablets for the treatment of cerebrovascular diseases; and (vii) Maisitong (麥思通®), a generic of pentoxifylline sustained-release tablets for the treatment of cerebral dysfunction.

Key products related to endocrine system diseases

The Company's commercialised product portfolio includes one drug for endocrine system diseases, namely Ruiantuo (瑞安妥®). Ruiantuo (瑞安妥®) is a generic of cinacalcet hydrochloride tablets selected in the Fifth National VBP Scheme and participated in the renewal of the 1st-8th batches of national VBP schemes.

Key products related to musculoskeletal system and pain-related diseases

The Company's commercialized product portfolio comprises two musculoskeletal system and pain-related drugs. (i) Antuofei (安妥飛®), a generic of celecoxib capsules for anti-inflammatory and analgesic use; and (ii) Anfeiping (安飛平®), a generic of diclofenac sodium enteric-coated tablets for anti-inflammatory use, which was selected in the VBP scheme of the alliance composed of 22 provinces led by Guangdong for diclofenac and other drugs in October 2025.

Key products related to nervous system diseases

The Company's commercialised product portfolio includes two drugs for nervous system diseases: (i) Anyoufan (安優凡®), which was selected in the provincial VBP scheme and participated in the renewal of the 1st-8th batches of national VBP schemes; (ii) Yinganke (盈安可®), a generic of cobamamide capsules for the treatment of neuroinflammation;

Key products related to other therapeutic area

The Company's commercialised product portfolio in other therapeutic areas consisted of three drugs: (i) Saixifu (賽西福®), a generic of hydroxychloroquine sulfate tablets for anti-inflammatory use, which was selected in the Tenth National VBP Scheme in December 2024; (ii) Jishuning (及舒寧®), a generic of cetirizine hydrochloride oral solution for anti-allergic use, which was selected in the Guangdong 21-Province Alliance VBP Scheme in October 2025; and (iii) Anruiying (安瑞盈®), a generic of sodium potassium magnesium calcium concentrate for injection for electrolyte supplementation.

The Company's commercialised products are competitively positioned globally for high prevalence medical conditions and their market positions are expected to grow or maintain at its current level.

Research and Development

With over a decade of experience, the Company has established an R&D team that covers the entire cycle of pharmaceutical R&D, including medicinal chemistry, formulation, preclinical research, quality control, quality assurance, clinical operation and regulatory affairs. The Company has built two product development platforms which form the bedrock of its R&D capabilities. These product development platforms include (i) the Multi-target Innovative Drug Development Platform ("**MultiSel-Opt Platform**"), through which the Company facilitates the screening, discovery and optimisation of compound candidates in preclinical research and advances development candidates in clinical studies; and (ii) the Generic Drug Development Platform, through which the Company continues to develop drug candidates with market potential. They enable the Company to continuously and quickly identify therapeutic targets with huge market potential and develop products towards commercialisation.

During the Reporting Period and up to the date of this announcement, the Company had remarkable R&D achievements in the following product candidates.

R&D progress for the product candidates

The Company is actively exploring the combination potential of the major innovative drugs C019199 and HXP089 and another major innovative drug HX9428 to become the first oral drug therapy for nAMD/DME/RVO. The Company may also explore potential license-out opportunities or other collaboration arrangements for its innovative drug candidates in overseas markets in the future.

C019199

C019199 is a multi-mechanism immuno-modulator targeting CSF-1R/DDR1/VEGFR2, which is the first innovative drug candidate developed from the MultiSel-Opt Platform. The Company is developing C019199 both as monotherapy and in combination therapies with drugs such as anti-PD-1 mAbs for a variety of oncology diseases. C019199's indications include, among others, osteosarcoma, breast cancer, colorectal cancer, pancreatic cancer and tenosynovial giant cell tumor (TGCT). In July 2020, the Company obtained the Investigational New Drug Application (IND) approval from the NMPA for C019199. As of 30 June 2026, the Company had (i) completed Phase Ia clinical trials and initiated Phase Ib/II clinical trials for osteosarcoma and TGCT; and (ii) completed Phase I clinical trial and initiated Phase II clinical trial in different types of solid tumors for combination therapy with anti-PD-1 mAbs. In the second quarter of 2026, the Company has initiated Phase III clinical trials for C019199 for osteosarcoma in China. In the U.S., the Company also expects to initiate Phase I/II clinical trials for osteosarcoma after the Company obtains Food and Drug Administration (FDA) IND approval.

HXP056

HX9428 is a candidate drug molecule of HXP056, an innovative drug project independently developed by the Company. It is designed to provide an oral therapy for the treatment of ocular fundus diseases. HX9428 is expected to overcome the technical challenges of achieving BRB penetration to reach the retinal disease site, while simultaneously optimising systemic exposure to ensure patients' safety. HX9428 has the potential to become the world's first oral therapy for the treatment of the said retinal diseases, rendering both a significant technological advancement and an explosive global market potential.

Preliminary data from the Phase I clinical study of HX9428 in nAMD demonstrated favourable safety and tolerability, with a good dose-exposure relationship. Furthermore, in both treatment-naive and previously treated patients with nAMD enrolled in Phase I clinical trial, initial improvements in both fundus morphology and retinal function were observed. Based on these promising early results, the Company has already commenced patient enrollment for the Phase II expansion study in China in the fourth quarter of 2025 while the Phase I dose escalation was still ongoing. The Company's goal is to expeditiously evaluate and determine the optimal dose for treatment, thereby laying a solid foundation for the upcoming Phase III clinical studies in the near future. Furthermore, given the favorable efficacy and safety trends demonstrated by HX9428 in its domestic clinical studies, as of the date of this announcement, the U.S. Food and Drug Administration (FDA) has approved the initiation of the Phase II clinical trial of HX9428 in the U.S. and granted HX9428 Fast Track Designation. At the same time, the Company officially commenced the second Phase II clinical trial of HX9428 (Registration No.: CTR20262884) for the treatment of nAMD in China, and the related information has been published on the Drug Clinical Trial Registration and Information Disclosure Platform of the Center for Drug Evaluation (CDE) of the NMPA. This study is a randomized and positive-controlled Phase II clinical trial further initiated by the Company based on the prior Phase I and Phase II dose expansion studies of HX9428.

HXP089

HXP089 is another innovative drug candidate developed from the Company's MultiSel-Opt Platform. Its R&D and design consistently adhere to the concept of "delivering synergistic therapeutic effects through multiple mechanisms of action with a single molecule". It is intended for the treatment of glioblastoma (GBM). During the molecular design process, HXP089 placed significant emphasis on the targeted optimization of compound exposure in target tissues. This ensures that the final compound candidate possesses strong blood-brain barrier (BBB) penetration capabilities and achieves coordinated modulation of multiple key disease pathways. It is expected to bring new therapeutic hope to GBM patients, addressing the long-standing unmet medical need for effective treatment options. As at the date of this announcement, the IND application for HXP089 for the treatment of GBM has been approved by the NMPA. The Company expects to initiate the Phase I/II clinical trial for the treatment of GBM in the third quarter of 2026.

Marketing and Collaboration

Manufacturing

During the Reporting Period, the Company, as a marketing authorisation holder ("**MAH**"), primarily focused on the R&D and commercialisation of the generic and innovative drug candidates in the pipeline. As of 30 June 2026, rebamipide tablets, cobamamide capsules, amlodipine besilate and atorvastatin calcium tablets (5mg/10mg), amlodipine besilate and atorvastatin calcium tablets (5mg/20mg), celecoxib capsules, mosapride citrate tablets, valsartan and amlodipine tablets (I) and diclofenac sodium enteric-coated tablets have completed site transfers to the Company's manufacturing base. Among these products, cobamamide capsules have been fully transitioned to in-house manufacturing, while the remaining products are manufactured through a parallel combination of in-house manufacturing and outsourcing to qualified contract manufacturing organisations (CMOs). Currently, the Company owns the manufacturing facility in Fuzhou with a total gross floor area of around 90,000 sq.m. As of 30 June 2026, the Company has obtained the drug manufacturing license issued by the Fujian Medical Products Administration (福建省藥品監督管理局), and has completed the installation of production lines for oral solid dosage production with designed annual production capacity of 2.0 billion tablets and capsules.

Outlook

Looking ahead, the Company's overall financial and business position remains robust and continues to improve subsequent to 30 June 2026, driven by the successful execution of our core strategies. We are steadily advancing along our established innovation-driven trajectory, with our three core pipelines achieving consecutive key milestones: C019199 has successfully initiated its Phase III clinical trials for osteosarcoma in China and is planned for expansion into the U.S. market; HX9428 has completed its Phase I clinical study and is currently in the Phase II stage. It is positioned to become the world's first oral therapy for fundus diseases, and we are actively preparing for its U.S. clinical scheme; our next-generation glioma candidate, HXP089, is expected to enter clinical trials in the third quarter of 2026. These developments validate the technical strength of our proprietary MultiSel-Opt Platform and align with the growing global capital market interest in China's indigenous innovation. International investors and multinational pharmaceutical companies increasingly recognize the cost effectiveness and speed advantages of early-stage R&D in China. Backed by solid financial reserves, including robust operating cash flows and proceeds from our 2025 global offering, our R&D team can efficiently drive full-cycle development from preclinical exploration to late-stage trials without capital constraints, ensuring high standards in both scientific innovation and execution. Looking forward, leveraging our formidable technological moat in multi-target small molecule design, the Company will continue to consolidate its leading position in China's innovative drug sector and accelerate its pursuit of becoming a world-class biopharmaceutical enterprise.

FINANCIAL REVIEW

Operating Income

The breakdown of operating income from pharmaceutical products by marketed products are set out as follows:

	For the six months ended 30 June			
	2026		2025	
	Amount (RMB'000)	**(%)**	Amount (RMB'000)	(%)
Haihuitong (海慧通®)	**159,264**	**51.20**	146,380	48.85
Anbili (安必力®)	**86,096**	**27.68**	85,912	28.67
Ruiantuo (瑞安妥®)	**19,158**	**6.16**	20,462	6.83
Saixifu (賽西福®)	**15,859**	**5.10**	22,800	7.61
Haibiping (海必平®)	**14,742**	**4.73**	13,904	4.64
Others	**15,948**	**5.13**	10,209	3.40
Total	**311,067**	**100.00**	299,667	100.00

Revenue from sales of pharmaceutical products for the six months ended 30 June 2026 amounted to RMB311,067,000, representing an increase of 3.80% from RMB299,667,000 for the six months ended 30 June 2025. The increase was primarily because Haihuitong (海慧通®) added a newly selected specification (5mg/20mg × 14 tablets) under the national VBP scheme in 2025, which effectively drove hospital channel development and continuous end-market sales growth.

Operating Costs

Operating costs for the six months ended 30 June 2026 amounted to RMB56,462,000, representing an increase of 39.02% from RMB40,615,000 for the six months ended 30 June 2025, primarily due to the gradual transition of certain commercialised products from the Contract Manufacturing Organization (CMO) model to in-house manufacturing model. During the Reporting Period, the relevant production lines were still in the capacity ramp-up phase, and the capacity utilisation had not yet reached the optimal level, resulting in an increase in the fixed asset depreciation and manufacturing overhead per unit of product. As capacity utilisation gradually improves and economies of scale are realised, the unit production cost is expected to be lower. The establishment of the in-house manufacturing model will fundamentally enhance the Company's ability to maintain an autonomous and controllable supply chain, and lay a solid foundation for subsequent cost reduction through scaled production.

Other Income

Other income for the six months ended 30 June 2026 amounted to RMB6,366,000, representing an increase of 747.67% from RMB751,000 for the six months ended 30 June 2025, primarily attributable to an increase in government grants received during the Period.

Administrative Expenses

Administrative expenses for the six months ended 30 June 2026 amounted to RMB12,611,000, representing an increase of 9.41% from RMB11,526,000 for the six months ended 30 June 2025. The increase was primarily attributable to higher professional service fees incurred following the Company's listing compared to the corresponding period.

Selling Expenses

Selling expenses for the six months ended 30 June 2026 amounted to RMB99,356,000, representing a decrease of 0.49% from RMB99,849,000 for the six months ended 30 June 2025.

Finance Expenses

Finance expenses of the Group for the six months ended 30 June 2026 amounted to RMB11,759,000, representing an increase of 321.02% from RMB2,793,000 for the six months ended 30 June 2025, primarily attributable to foreign exchange gains or losses arising from the translation of foreign currencies into Renminbi at the end of the period.

R&D Expenses

R&D expenses for the six months ended 30 June 2026 amounted to RMB40,762,000, representing an increase of 50.32% from RMB27,116,000 for the six months ended 30 June 2025, primarily due to the advancement of clinical progress of the Group's innovative drug projects, resulting in higher clinical trial expenses.

Net Profit

Net profit for the six months ended 30 June 2026 amounted to RMB81,049,000, representing a decrease of 24.82% from RMB107,806,000 for the six months ended 30 June 2025, primarily due to depreciation expenses of RMB7,987,000 arising from the commencement of operations at the subsidiary's production base compared to the corresponding period, and higher R&D expenses in the year.

Liquidity and Sources of Funds

The Company's monetary funds increased from approximately RMB645,054,000 as of 31 December 2025 to approximately RMB1,018,978,000 as of 30 June 2026. The Company's primary sources of liquidity are its operating cash flows and the proceeds from the Global Offering. The Board is of the opinion that the Company has sufficient resources to sustain its management and meet its foreseeable capital expenditure requirements.

Gearing Ratio

The Group's gearing ratio (being total liabilities divided by total assets) increased from 13.70% as of 31 December 2025 to 15.11% as of 30 June 2026, primarily attributable to the increase in the amount of government grants related to assets received during the Period that were recognized as deferred revenue.

Funding and Treasury Policies

The Group primarily finances its operations through cash generated from business operations and the net proceeds from the Global Offering. The Group's treasury activities are managed by its finance department in accordance with the Group's internal monetary fund management policies and external investment management policies. The primary objectives of the Group's treasury management are to safeguard the Group's assets, manage its liquidity position and minimise financial risks. The finance department is responsible for monitoring and managing the Group's cash flows, foreign exchange exposures and investment activities under the oversight of the management and the Board.

Foreign Exchange and Exchange Rate Risk

The Group primarily operates in the PRC and is exposed to foreign currency risk arising from fluctuations in exchange rate between RMB and other currencies in which the Group conducts its business. The Group did not enter into any hedging transactions in respect of foreign currency risk as at 30 June 2026. The Directors expect that the fluctuation of the RMB exchange rate will not have a material adverse effect on the operation of the Group.

Hedging Activities

As at 30 June 2026, the Group did not use any financial instruments for hedging purposes and did not enter into any hedging transactions in respect of foreign currency risk or interest rate risk.

OTHER INFORMATION

Material Investments

Save as disclosed in the section headed "Future Plans and Use of Proceeds" in the prospectus of the Company issued on 9 October 2025 and further updated in the section headed "Use of Proceeds" below in this announcement, the Group does not have any future plans for material investments or capital assets as at 30 June 2026.

Material Acquisitions and Disposals

The Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies during the six months ended 30 June 2026.

Significant Investments

As of 30 June 2026, the Group had total assets of RMB1,966,288,000. The table below sets out the fair value of each investment and its percentage of the Group's total assets as at 30 June 2026:

Item	Fair value at the end of the period (RMB)	Percentage of the Group's total assets (%)
(1) Financial assets held for trading	172,386,000.00	8.77
(2) Other non-current financial assets	25,337,000.00	1.29
(3) Other equity instrument investments	19,653,000.00	1.00
Total	217,376,000.00	11.06

As at 30 June 2026, the Company's financial assets held for trading primarily consisted of:

(1) Financial assets held for trading mainly are the money market funds (classified as current financial assets at fair value through profit or loss). The funds were used to subscribe for wealth management products managed by various fund managers in Chinese Mainland, in the aggregate principal amount of RMB170,310,000. All applicable percentage ratios in respect of each investment were below 5% and none of them individually constituted a disclosable transaction of the Company under Chapter 14 of the Listing Rules. The underlying assets of these funds in Chinese Mainland mainly comprise cash, short-term debt instruments issued by municipal governments and other financial instruments.

(2) Other non-current financial assets mainly are the convertible notes issued by an equity investment (classified as other non-current financial assets at fair value through profit or loss). During the six months ended 30 June 2026, the Company held convertible notes in the principal amount of RMB20,000,000. The convertible notes are classified as other non-current assets because the Directors expect that the financial asset will not be realized until more than twelve months after the end of the Reporting Period. The fair value of the convertible notes is determined based on a valuation performed by an independent external valuer using a binomial valuation model. The key inputs to the model include the coupon rate, conversion price and expected volatility of comparable companies.

(3) The Company made a cash investment of RMB20,000,000 for an approximately 4.58% equity interest in a private entity incorporated in the Cayman Islands (the "**Investment**"). The entity is an independent third party principally engaged in the business of providing treatment technologies for nervous injury and degenerative diseases. The capital injection was completed in July 2023. The Investment is held for long-term strategic purposes rather than for trading, and is therefore designated as an equity instrument at fair value through other comprehensive income.

All of the above products were funded by the Company's internal working capital. The proceeds from the initial public offering were not used for any of the aforementioned investment activities.

Pledge of Assets

As at 30 June 2026, the Group did not have any assets pledged to secure its loans and banking facilities.

Litigation and Contingent Liabilities

The Company was not involved in any material litigation or arbitration as of 30 June 2026. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group as at 30 June 2026 and up to the date of this announcement. As at 30 June 2026, the Group did not have any material contingent liabilities.

Events after the Reporting Period

There were no significant events affecting the Group that occurred after 30 June 2026 and up to the date of this announcement.

Future Plans for Material Investments or Capital Assets

Save as disclosed in this announcement, the Group did not have specific plans for material investments or capital asset acquisitions as at the date of this announcement.

Use of Proceeds

The Company completed its Global Offering on the Stock Exchange on 20 October 2025. After deducting underwriting commissions and other expenses payable in connection with the Global Offering, the net proceeds from the Global Offering amounted to approximately HK$940.13 million.

The intended allocation of net proceeds as set out in the Prospectus and the details of net proceeds of the Global Offering (totalling approximately RMB173.55 million) utilised on 30 June 2026, are summarised as follows:

No.	Intended Use	Approximate % of net proceeds	Allocated amount (HK$ million)	Net proceed unutilised at the beginning of the Reporting Period (HK$ million)	Amount utilised during the Reporting Period (HK$ million)	Amount utilised as at 30 June 2026 (HK$ million)	Unutilised amount as at 30 June 2026 (HK$ million)	Expected timeline for full utilisation
1	Continuous investment in R&D to advance drug candidates in the pipeline and to enrich the product portfolio (including approximately 40.0% for R&D of innovative drugs and approximately 12.0% for R&D of generic drugs)	52.0%	488.87	472.02	38.32	55.17	433.70	Before 31 December 2027
2	Improvement of the Group's R&D capacities and pursuit of collaboration opportunities	23.0%	216.23	212.09	11.05	15.19	201.04	Before 31 December 2027
3	Improvement and optimisation of the Group's R&D and manufacturing systems	7.0%	65.81	57.37	0.71	9.15	56.66	Before 31 December 2027
4	Enhancement of the Group's commercialisation capabilities and expansion of its market presence	8.0%	75.21	41.92	37.64	70.93	4.28	Before 31 December 2027
5	Working capital and other general corporate purposes	10.0%	94.01	82.07	11.17	23.11	70.90	Before 31 December 2027
	Total	100.0%	940.13	865.47	98.89	173.55	766.58	

As at 30 June 2026, the unutilised net proceeds from the Global Offering were deposited with licensed banks in the PRC and Hong Kong. The proceeds from the Global Offering have been and will continue to be utilised in accordance with the intended purposes as disclosed in the Prospectus. There has been no change in the intended use of the net proceeds from the Global Offering, nor has there been any material delay in the utilisation of such proceeds, as compared to the intentions previously disclosed in the Prospectus.

Interim Dividends

The Board does not recommend the distribution of an interim dividend for the six months ended 30 June 2026.

Corporate Governance Practices

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of its shareholders and to enhance corporate value and accountability. The Company has adopted the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 to the Listing Rules as its own code of corporate governance. From the listing date of the Company (i.e. 20 October 2025 to 30 June 2026, and up to the date of this announcement), the Company has complied with all applicable code provisions set out in Part 2 of the CG Code, save that Dr. Kang Xinshan serves as both the chairman of the Board and the general manager as discussed below.

Pursuant to code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Dr. Kang Xinshan, is our co-founder, chairman of the Board and general manager (same nature as chief executive). From the inception of our business, Dr. Kang has been responsible for the overall strategy planning of business operations and making key business and operational decisions of our Company. Since Dr. Kang is the key person for our Company's development and he will not undermine our Company's interests in any way under any circumstances, the Board believes that vesting the roles of both chairman of the Board and general manager in the same person has the benefit of ensuring consistent leadership within our Company and enables more effective and efficient overall strategic planning for our Company. The Board considers that the balance of power and authority for the present arrangement will not be impaired, and this structure will enable our Company to make and implement decisions promptly and effectively. The Board is currently composed of five executive Directors, one non-executive Directors and three independent non-executive Directors. Accordingly, the Board maintains a strong level of independence in its composition.

Model Code for Securities Transactions

The Company has adopted a code of conduct regarding Directors' securities transactions on terms no less exacting than the required standard set out in the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") set out in Appendix C3 to the Listing Rules. Specific enquiry has been made of all the Directors of the Company, the Directors have confirmed that they have complied with the Model Code from the listing date of the Company (i.e. 20 October 2025) to 30 June 2026.

Purchase, Sale or Redemption of Listed Securities

The Company or any of its subsidiaries redeemed 33,100 shares in issue (treasury shares) of the Company from the listing date of the Company (i.e. 20 October 2025) to 30 June 2026.

Board Committees

Audit Committee

The Audit Committee comprises three independent non-executive Directors, namely Ms. Pu Meiting, Mr.Lin Bin and Ms. Wang Shan Shan, with Ms. Pu Meiting as the chairperson of the Audit Committee. The primary responsibilities of the Audit Committee are to assist the Board in providing independent views on the effectiveness of the Group's financial reporting procedures, internal control and risk management systems, to oversee the audit process, and to perform other duties and responsibilities delegated by the Board.

The Audit Committee has reviewed together with the Board the accounting principles and policies adopted by the Group, the unaudited interim results and the unaudited consolidated financial statements of the Group for the Reporting Period. There is no disagreement between the Audit Committee and the Board regarding the accounting treatments. The Audit Committee also approved the Group's interim results and the consolidated financial statements for the Reporting Period and submitted them to the Board for approval.

Remuneration and Appraisal Committee

The Remuneration and Appraisal Committee comprises three members, namely Ms. Wang Shan Shan, Dr. Kang Xinshan, and Ms. Pu Meiting, with Ms. Wang Shan Shan as the chairperson of the Remuneration and Appraisal Committee. The Remuneration and Appraisal Committee's primary duties include, among others, researching the criteria for performance evaluation of Directors, Supervisors and senior management, formulating their job responsibilities, and reviewing and supervising the implementation of remuneration plans and incentive schemes.

Nomination Committee

The Nomination Committee comprises three members, namely, Ms. Wang Shan Shan, Dr. Kang Xinshan and Ms. Pu Meiting, with Ms. Wang Shan Shan as the chairperson of the Nomination Committee. The Nomination Committee's primary duties include, among others, researching standards and procedures for the election of Directors and senior management, conducting searches for suitable candidates, and making recommendations to the Board.

Strategy Committee

The Strategy Committee comprises three members, namely Dr. Kang Xinshan, Ms. Feng Yan and Mr. Lin Bin, with Dr. Kang Xinshan as the chairperson of the Strategy Committee. The primary duties of the Strategy Committee include researching and making recommendations on the Company's long-term development strategies, material investments, financing plans, capital operations and management projects, and other significant matters affecting the Company's development, while also supervising the implementation of these matters and handling any additional matters authorized by the Board.

PUBLICATION OF INTERIM RESULTS AND 2026 INTERIM REPORT ON THE WEBSITES OF THE STOCK EXCHANGE AND THE COMPANY

This announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the Company's website (www.hxpharma.com). In accordance with the requirements under the Listing Rules applicable to the Reporting Period, the 2026 interim report containing all the information about the Company in accordance with the requirements under the Listing Rules will be posted on the respective websites of the Stock Exchange and the Company in due course.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Executive Director, Chairman and General Manager

Fujian, the PRC, 28 August 2026

As at the date of this announcement, executive Directors are Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming, Dr. Li Junqing and Mr. Chen Tingze; non-executive Directors is Mr. Xu Dong; and independent non-executive Directors are Mr. Lin Bin, Ms. Wang Shan Shan and Ms. Pu Meiting.